JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Inclusion Criteria

• •Written informed consent.
• •Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
• •ECOG performance status score of 0 or 1.
• •Has been treated with at least one line of systemic therapy for that tumor type and stage.
• •Have documentation of confirmed TP53 Y220C mutation.
• •At least 1 measurable lesion per RECIST v1.1.
• •Adequate hematological, renal and hepatic function and appropriate coagulation condition.
• •Able to swallow and retain orally administered medication.